PDCD1 and glioblastoma: Enrichment analysis showed that C1-GBM displayed higher enrichment of the response signature, suggesting a greater likelihood of sensitivity to anti PD-1/PD-L1 therapy, whereas C2-GBM showed higher enrichment of the non-response signature, indicating potential resistance to pembrolizumab (Figure 8A).